Last reviewed · How we verify

Sabin IPV

Centers for Disease Control and Prevention, China · FDA-approved active Biologic

Sabin IPV is an inactivated polio vaccine that stimulates the immune system to produce antibodies against all three poliovirus serotypes, preventing poliomyelitis infection.

Sabin IPV is an inactivated polio vaccine that stimulates the immune system to produce antibodies against all three poliovirus serotypes, preventing poliomyelitis infection. Used for Prevention of poliomyelitis caused by poliovirus serotypes 1, 2, and 3.

At a glance

Generic nameSabin IPV
Also known asSabin strain Inactivated Poliovirus Vaccine
SponsorCenters for Disease Control and Prevention, China
Drug classinactivated viral vaccine
Targetpoliovirus serotypes 1, 2, and 3
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhaseFDA-approved

Mechanism of action

Sabin IPV contains chemically inactivated (killed) poliovirus particles of serotypes 1, 2, and 3. When administered, these antigens trigger both humoral (antibody) and cellular immune responses without causing disease. The resulting antibodies neutralize wild-type poliovirus and prevent viral replication in the gastrointestinal and nervous systems, thereby preventing paralytic poliomyelitis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: